Prelude Therapeutics Incorporated (PRLD) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Prelude Therapeutics Incorporated (NASDAQ: PRLD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.10 (-0.97% 1D, market cap $327.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRLD ranks #503 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRLD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TTRX (Turn Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -28.3%, cap $327.3M) and ENTA (Enanta Pharmaceuticals Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $324.7M). Among the 5-stock peer group, PRLD leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).
Per PRLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001678660), Prelude Therapeutics Incorporated generated $12.1M in revenue (+73.4% YoY), -$99.5M in net income, and -$56.4M in free cash flow against $141.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PRLD currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.40) and Max Pain ($4.31) forces dealer call-delta covering toward $7.17.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Prelude Therapeutics Incorporated (PRLD) slipped -0.97% to $4.10, trading at 52% of its 52-week range ($1.17 – $6.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and costs loom.
Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +73.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PRLD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PRLD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Prelude Therapeutics Incorporated (PRLD) ranks #503 by composite RQD confidence (41/100, grade D-) and #512 by equity capitalization ($327.2M). Within this direct 5-issuer industry benchmark cohort, PRLD leads on earnings valuation at N/A trailing P/E, while TTRX leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. PRLD currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRLD
ACTIVE
Prelude Therapeutics Incorporated | D- | 41/100 | — | — | -35.0% | -0.97% | $327.2M | Benchmark Subject |
| TTRX Turn Therapeutics Inc. | D- | 39/100 | — | — | -28.3% | -3.60% | $327.3M | /ttrx-vs-prld → |
| ENTA Enanta Pharmaceuticals Inc. | E | 20/100 | — | — | -35.0% | -3.46% | $324.7M | /enta-vs-prld → |
| ARCT Arcturus Therapeutics Holdings Inc. | E | 25/100 | — | — | -35.0% | +0.66% | $345.3M | /arct-vs-prld → |
| AVIR Atea Pharmaceuticals Inc. | E | 34/100 | — | — | -35.0% | +0.94% | $345.7M | /avir-vs-prld → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prelude Therapeutics Incorporated (PRLD) reported GAAP revenue of $12.1M (+73.4% vs. FY2024 revenue of $7.0M ) , GAAP net income of -$99.5M, operating cash flow of -$56.3M, and free cash flow of -$56.4M (+45.6% YoY). On the balance sheet, PRLD closed FY2025 with $141.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $12.1M | -$99.5M | -$56.3M | -$56.4M | $141.3M | — |
| FY2024 (FY) | 2024-12-31 | $7.0M | -$127.2M | -$102.9M | -$103.7M | $175.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$121.8M | -$107.1M | -$107.1M | — | — |
As of 2026-11-02, Prelude Therapeutics Incorporated (NASDAQ: PRLD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.10 (-0.97% 1D, market cap $327.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRLD ranks #503 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRLD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TTRX (Turn Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -28.3%, cap $327.3M) and ENTA (Enanta Pharmaceuticals Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $324.7M). Among the 5-stock peer group, PRLD leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).
Per PRLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001678660), Prelude Therapeutics Incorporated generated $12.1M in revenue (+73.4% YoY), -$99.5M in net income, and -$56.4M in free cash flow against $141.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PRLD last traded at $4.10 (-0.97% on volume of 201,328 shares), positioning the stock -6.82% below its 50-day simple moving average ($4.40) and +1.99% above its 200-day simple moving average ($4.02). Across its 52-week range of $1.17 to $6.83, PRLD sits at the 51.8% percentile with a 14-day RSI of 54.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.59 to $4.61).
Why PRLD Stock slipped -0.97% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).